Cystatin C reduction ratio depends on normalized blood liters processed and fluid removal during hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 2, 2011, Pages 319-325

  Huang, Shih Han S ^a   Filler, Guido ^a   Yasin, Abeer ^a   Lindsay, Robert M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; PROTEIN; UREA;

AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CREATININE REDUCTION RATIO; CROSS-SECTIONAL STUDY; CYSTATIN C REDUCTION RATIO; HEMODIALYSIS; HUMAN; PILOT STUDY; RENAL SYSTEM PARAMETERS; ULTRAFILTRATION; ULTRAFILTRATION VOLUME; UREA REDUCTION RATIO;

AGED; BIOLOGICAL MARKERS; CREATININE; CROSS-SECTIONAL STUDIES; CYSTATIN C; HUMANS; KIDNEY FAILURE, CHRONIC; KINETICS; MIDDLE AGED; MODELS, BIOLOGICAL; ONTARIO; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RENAL DIALYSIS; TREATMENT OUTCOME; UREA;

EID: 79951928291     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05290610     Document Type: Article

References (29)

1. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S: Measurement of muscle mass in humans: Validity of the 24-hour urinary creatinine method. Am J Clin Nutr 37: 478-494, 1983 (Pubitemid 13086433)
2. National Kidney Foundation: 2006 updates clinical practice guidelines and recommendations. Hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 48[Suppl 1]: S1-S322, 2006
3. Cheung AK: Hemodilaysis and hemodialtration. In: Primer on kidney diseases, 4th edition, edited by Greenberg A, Philadelphia, Elsevier Saunders, 2005, pp 464-476
4. Daugirdas JT: Physiologic principles and urea kinetic modeling. In: Handbook of dialysis, 4th edition, edited by Daugirdas JT, Blake PG, Ing TS, Philadelphia, Lippincott Williams & Wilkins, 2007, pp 25-58
5. Suri R, Blake P: Adequacy of hemodialysis. In: Replacement of renal function by dialysis, 5th edition, edited by Horl WH, Koch KM, Lindsay RM, Ronco C, London, Kluwer Academic Publishers, 2004, pp 597-638
6. Gotch FA: The current place of urea kinetic modeling with respect to different dialysis modalities. Nephrol Dial Transplant 13[Suppl 6]: 10-14, 1998
7. Prigent A: Monitoring renal function and limitations of renal function tests. Semin Nucl Med 38: 32-46, 2008
8. Sharma AP, Kathiravelu A, Nadarajah R, Yasin A, Filler G: Body mass does not have a clinically relevant effect on cystatin C eGFR in children. Nephrol Dial Transplant 24: 470-474, 2009
9. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez- Brú C, Grubb A: Cystatin C as a marker of GFR: History, indications, and future research. Rev Clin Biochem 38: 1-8, 2005 (Pubitemid 39647648)
10. Park JS, Kim GH, Kang CM, Lee CH: Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules. Korean J Intern Med 25: 77-81, 2010
11. Manetti L, Pardini E, Genovesi M, Compomori A, Grasso L, Morselli LL, Lupi I, Pellegrini G, Bartalona L, Bogazzi F, Martino E: Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 4: 346-349, 2005 (Pubitemid 43162754)
12. Wasen E, Isoaho R, Vahlberg T, Kivela SL, Irjala K: Association between markers of renal function and C reactive protein level in the elderly; confounding by functional status. Scan J Clin Lab Invest 68: 484-491, 2008
13. Foster J, Reisman W, Lepage N, Filler G: Influence of commonly used drugs on the accuracy of cystatin C-derived glomerular filtration rate. Pediatr Nephrol 21: 235-238, 2006 (Pubitemid 43115877)
14. Simonsen O, Grubb A, Thysell H: The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45: 97-101, 1985 (Pubitemid 15106618)
15. Löfberg H, Grubb AO: Quantitation of g-trace in human biological fluids: indications for production in the central nervous system. Scand J Clin Lab Invest 39: 619-626, 1979 (Pubitemid 10214387)
16. Dharnidharka V, Kwon C, Stevens G: Cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 40: 221-226, 2002 (Pubitemid 34827638)
17. Delaney MP, Stevens PE, Al Hasani M, Stowe HJ, Judge C, Lamb EJ: Relationship of serum cystatin C to peritoneal and renal clearance measures in peritoneal dialysis: A cross-sectional study. Am J Kidney Dis 51: 278-284, 2008
18. Hoek FJ, Korevaar JC, Dekker FW, Bioeschoten EW, Krediet RT: Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 11: 1633-1638, 2007 (Pubitemid 47073762)
19. Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lindsay RM: Cystatin C levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol 4: 1606-1610, 2009
20. Thysell H, Grubb A, Lindholm T, Ljunggren L, Mårtensson L: Cystatin C: A new marker of biocompatibility or a good marker for the redistribution of LMW proteins during hemodialysis? ASAIO Trans 34: 202-204, 1988
21. Lindström V, Grubb A, Alquist Hegbrant M, Christensson A: Different elimination patterns of β-trace protein, β2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest 68: 685-691, 2008
22. Sambasivan AS, Lepage N, Filler G: Cystatin C intrapatient variability in children with chronic kidney disease is less than serum creatinine. Clin Chem 51: 2215-2216, 2005 (Pubitemid 41532660)
23. Zingraff J, Caillat-Vigneron N, Ureña P, Gagné ER, Bererhi L, Moretti JL, Bardin T, Drüeke TB: Plasma kinetics of 125I-labelled amyloid P component in beta 2M amyloidosis: A possible approach to quantitate disease activity. Nephrol Dial Transplant 10: 223-229, 1995
24. Kristensen K, Lindström V, Schmidt C, Blirup-Jensen S, Grubb A, Wide-Swensson D, Strevens H: Temporal changes of the plasma levels of cystatin C, beta-trace protein, beta2-microglobulin, urate and creatinine during pregnancy indicate continuous alterations in the renal filtration process. Scand J Clin Lab Invest 67: 612-618, 2007 (Pubitemid 351411738)
25. Clark WR, Macias WL, Molitoris BA, Wang NH: Membrane adsorbtion of beta 2-microglubulin: Equilibrium and kinetic characterization. Kidney Int 46: 1140-1146, 1994 (Pubitemid 24319954)
26. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002
27. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002 (Pubitemid 34441412)
28. Ix JH, Shlipak MG, Chertow GM, Whooley MA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 115: 173-179, 2007 (Pubitemid 46105715)
29. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GH, Collins AJ, Levey AS, Sarnak MJ: Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 147: 19-27, 2007 (Pubitemid 351664630)